[Economic assessment of Caelyx versus topotecan in advanced ovarian cancer].
Ovarian cancer is the most frequent cause of death due to gynecologic malignancy in both the United States and in Europe. A phase III investigation compared second line treatment Caelyx with topotecan in patients with advanced epithelial ovarian carcinoma who failed a first-line platinum-containing regimen. A total of 474 patients were enrolled Although no significant advantage of Caelyx over topotecan with regards to overall survival and progression was found, there were fewer adverse events in the Caelyx arm and Caelyx had significantly better quality of life profile. We conducted a cost minimization analysis of both treatment arms. Costs were estimated from the viewpoint of the hospital, over the duration of the study period (12 weeks). The frequency of adverse events was derived from the trial's CRF, the treatment patterns of adverse events was estimated for each type of adverse event and each grade for a given type of adverse event. Costs included that of the drug and management of adverse events. Because of uncertainty on actual time spent in French hospitals, administration costs were not valued. Adverse events valued in the analysis were: stomatitis/ pharyngitis, PPE, nausea/vomiting diarrhea, anemia, thrombocytopenia, neutropenia, sepsis, fever. Drug costs and costs of blood products were valued using the purchase price by the hospital, costs of tests and hospital days were estimated from the hospital's accounting system. The drug cost per patient was 8,735 euros for Caelyx and 6,196 euros for topotecan, the cost of adverse events were 528 and 3,632 euros for Caelyx and topotecan respectively, due to the high rate of adverse events in patient treated with topotecan. The total costs were 9,279 and 9,938 for Caefyx and topotecan respectively.


CONCLUSIONS
the least expensive management for second line advanced ovarian cancer is Caelyx. Although the initial cost of the drug is higher, the reduced number of adverse events results in a lower total cost. Because treatment with Caelyx is also associated with a better of quality of life, this treatment strategy could be considered dominant.
Girre
Véronique
V
Service d'oncologie Hôtel-Dieu, AP-HP, Hôpital Herri-Mondor, 51 avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
Pujade-Lauraine
Eric
E
Durand-Zaleski
Isabelle
I
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004317:Doxorubicin / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D016527:Drug Costs; D005260:Female; D017721:Hospital Costs; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000191:economics*; D011788:Quality of Life; D019772:Topotecan / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D019772:Topotecan; D004317:Doxorubicin